Five Scorching Hot Stocks Screaming Higher

It was all good until the Donald Jr. email hit the wires, then the market dipped quickly. Good news is for the most part the market recovered on into the close. The bad news is, the damage is done and what looked to be an extension of yesterday’s rally flat ran out of gas.

Check out Dave’s Daily Dive video above where I break down the market action today!!!

Each day I, Dave Bartosiak of Zacks.com (Twitter @bartosiastics) dive into the charts, pointing out key price action and levels for you to watch.

But it doesn’t stop there because the highlight of today’s video, which you can see for free by clicking above, is where I uncover five Zacks Rank #1 (Strong Buy) stocks that are breaking out to new 52-week highs today. These stocks have a ton of momentum behind them and are charging higher. The list of stocks he covers today include:

Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Carolina Financial (NASDAQ:CARO)

Carolina Financial Corporation operates as a bank holding company for CresCom Bank that provides a range of commercial and retail banking financial services in South Carolina and North Carolina. The company operates in Community Banking and Wholesale Mortgage Banking segments.

Deere & Co (NYSE:DE)

Deere & Company, together with its subsidiaries, manufactures and distributes agriculture and turf, and construction and forestry equipment worldwide.

Exelixis (NASDAQ:EXEL)

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company’s products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil.

ING Group (NYSE:ING)

ING Groep (AS:INGA) N.V., a financial institution, provides various banking products and services to individuals, small and medium-sized enterprises, and mid-corporates. The company operates through Retail Netherlands, Retail Belgium, Retail Germany, Retail Other, and Wholesale Banking segments.

Now See All Our Private Trades

While today's Zacks Rank #1 new additions are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>